Testing a new drug for people with certain autoimmune diseases that have come back or not responded to treatment
Treatments studied
Part of Immune system & allergy clinical trials.
This trial is testing a new injection, NEUK203-215, in adults aged 18-65 with certain autoimmune diseases (like lupus, scleroderma, inflammatory myopathy, or a skin blistering condition) that have relapsed or not responded to standard therapy. The goal is to see if it is safe, tolerable, and may help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with one of these autoimmune diseases: systemic lupus erythematosus, diffuse systemic sclerosis (hardening of the skin), inflammatory myopathy (muscle inflammation), or autoimmune bullous dermatosis (blistering skin disease).
- Your disease has come back (relapsed) or has not responded to previous treatments (refractory).
- Your major organs (like heart, lungs, liver, kidneys) must be working well enough.
- You cannot have had a heart attack, heart failure, or other serious heart problems in the last 6 months, and no cancer in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication called ADI-001 to see if it can help people with rheumatoid arthritis. It is for adults who meet the standard criteria for RA and are in generally good health otherwise.
This trial tests a new cell therapy called UTAA91 for people with autoimmune diseases that have not responded to standard treatments. It aims to see if this treatment can help control the disease.
This trial tests an investigational drug called AZD0120 in adults with lupus that hasn't improved with standard treatments. The goal is to see if it's safe and works well for people with lupus-related organ problems.
This early-stage trial tests whether HN2302, a new type of genetic medicine, is safe and helps patients with lupus or systemic sclerosis. Researchers want to see if it can reduce symptoms and improve organ function in people with these autoimmune conditions.
This trial tests a new cell therapy, FT819, for people with certain autoimmune diseases like lupus, vasculitis, myositis, or scleroderma that haven't improved with at least two previous treatments. The goal is to see if it can help control the disease.
This trial tests a new treatment called CABA-201, which is a type of immune cell therapy (CAR T cells) for people with active lupus. The goal is to see if it's safe and can help control lupus symptoms.
Hear when a new Autoimmune trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.